Tracing the Natural Course of Visual Acuity and Quality of Life in Neovascular Age-related Macular Degeneration: a Systematic Review and Quality of Life Study

Overview

Journal BMC Ophthalmol

Publisher Biomed Central

Specialty Ophthalmology

Date 2017 Jul 12

PMID 28693519

Citations 14

Authors

Mari Elshout

Carroll A Webers

Margriet I van der Reis

Yvonne de Jong-Hesse

Jan S Schouten

Affiliations

Soon will be listed here.

Abstract

Background: Describing the natural course of neovascular age-related macular degeneration (nAMD) is essential in discussing prognosis and treatment options with patients and to support cost-effectiveness studies.

Methods: First, we performed a literature search in PubMed, Embase, and Cochrane. We included randomized clinical trials and prospective observational studies reporting visual acuity (VA) in non-treated patients, 24 studies in total. We integrated VA data using best fit on Lineweaver-Burke plots and modelled with non-linear regression using reciprocal terms. Second, we performed a quality-of-life (QoL) study in nAMD patients. We measured VA with Radner reading charts and QoL with the Health Utilities Index issue 3 (HUI-3) questionnaire in 184 participants. We studied the relation VA-QoL with linear regression. Third, with Monte Carlo simulation, we integrated the VA model from the literature review and the relation VA-QoL from the QoL study.

Results: Visual acuity was 0.4 and 0.07 after 5 years in the better-seeing, and worse-seeing eye, respectively. After 4.3 years, VA was <0.5 in the better-seeing eye; <0.3 after 7 years; 0.05 after 17 years. QoL score decreased from 0.6 to 0.45 after 10 years.

Conclusions: The natural course of nAMD in both eyes needs to be considered when informing patients. Visual acuity in the best eye decreases to below 0.5 in 4.3 years. This affects QoL significantly.

Citing Articles

Clinical and Socioeconomic Burden of Retinal Diseases: Can Biosimilars Add Value? A Narrative Review.

Hariprasad S, Holz F, Asche C, Issa A, Mora O, Keady S Ophthalmol Ther. 2025; .

PMID: 40009268 DOI: 10.1007/s40123-025-01104-3.

Cochrane corner: artificial intelligence for diagnosing exudative age-related macular degeneration.

Ong A, Hogg H, Keane P Eye (Lond). 2025; 39(4):620-621.

PMID: 39833576 PMC: 11885809. DOI: 10.1038/s41433-025-03599-3.

Low Vision Rehabilitation Referral Characteristics for Patients with Neovascular Age-Related Macular Degeneration.

Archambault S, Sweeny C, Bhardwaj M, Ramsey D Healthcare (Basel). 2025; 13(1.

PMID: 39791671 PMC: 11720129. DOI: 10.3390/healthcare13010064.

Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan.

Yanagi Y, Takahashi K, Iida T, Gomi F, Morii J, Kunikane E Ophthalmol Ther. 2023; 12(4):2005-2021.

PMID: 37171557 PMC: 10287869. DOI: 10.1007/s40123-023-00715-y.

Office Examinations-Directed Treatment Paradigms Reduce Travel Burden, Decrease Treatment Cost, and Improve Quality-Adjusted Life-Years for Patients With Exudative Age-Related Macular Degeneration Undergoing Antivascular Endothelial Growth Factor....

Emerson G, Thompson J, Vo L, Mason R, Lee G, Leder H J Vitreoretin Dis. 2023; 4(6):472-478.

PMID: 37007662 PMC: 9976064. DOI: 10.1177/2474126420935819.

References

Shah A, Del Priore L . Progressive visual loss in subfoveal exudation in age-related macular degeneration: a meta-analysis using Lineweaver-Burke plots. Am J Ophthalmol. 2006; 143(1):83-89. DOI: 10.1016/j.ajo.2006.09.043. View

Medeiros F, Gracitelli C, Boer E, Weinreb R, Zangwill L, Rosen P . Longitudinal changes in quality of life and rates of progressive visual field loss in glaucoma patients. Ophthalmology. 2014; 122(2):293-301. PMC: 4306625. DOI: 10.1016/j.ophtha.2014.08.014. View

Wong T, Wong T, Chakravarthy U, Klein R, Mitchell P, Zlateva G . The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2007; 115(1):116-26. DOI: 10.1016/j.ophtha.2007.03.008. View

Kaiser P . Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial. Curr Med Res Opin. 2009; 25(8):1853-60. DOI: 10.1185/03007990903038616. View

Pece A, Bolognesi G, Introini U, Pacelli G, Calori G, Brancato R . Indocyanine green angiography of well-defined plaque choroidal neovascularization in age-related macular degeneration. Arch Ophthalmol. 2000; 118(5):630-4. DOI: 10.1001/archopht.118.5.630. View

Blinder K, Bradley S, Bressler N, Bressler S, Donati G, Hao Y . Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003; 136(3):407-18. DOI: 10.1016/s0002-9394(03)00223-x. View

Schneider U, Gelisken F, Inhoffen W . Natural course of occult choroidal neovascularization in age-related macular degeneration: development of classic lesions in fluorescein angiography. Acta Ophthalmol Scand. 2005; 83(2):141-7. DOI: 10.1111/j.1600-0420.2005.00443.x. View

Mandai M, Takahashi M, Miyamoto H, Hiroshiba N, Kimura H, Ogura Y . Long-term outcome after radiation therapy for subfoveal choroidal neovascularization associated with age-related macular degeneration. Jpn J Ophthalmol. 2000; 44(5):530-7. DOI: 10.1016/s0021-5155(00)00217-3. View

van Gestel A, Severens J, Webers C, Beckers H, Jansonius N, Schouten J . Modeling complex treatment strategies: construction and validation of a discrete event simulation model for glaucoma. Value Health. 2010; 13(4):358-67. DOI: 10.1111/j.1524-4733.2009.00678.x. View

10.

Tholen A, Meister A, Bernasconi P, Messmer E . [Radiotherapy for choroidal neovascularization (CNV) in age-related macular degeneration (AMD)]. Klin Monbl Augenheilkd. 2000; 216(2):112-5. DOI: 10.1055/s-2000-10528. View

11.

Boyer D, Antoszyk A, Awh C, Bhisitkul R, Shapiro H, Acharya N . Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007; 114(2):246-52. DOI: 10.1016/j.ophtha.2006.10.045. View

12.

Feeny D, Furlong W, Torrance G, Goldsmith C, Zhu Z, DePauw S . Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care. 2002; 40(2):113-28. DOI: 10.1097/00005650-200202000-00006. View

13.

Azab M, Boyer D, Bressler N, Bressler S, Cihelkova I, Hao Y . Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol. 2005; 123(4):448-57. DOI: 10.1001/archopht.123.4.448. View

14.

Schmier J, Hulme-Lowe C . Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges. Pharmacoeconomics. 2015; 34(3):259-72. DOI: 10.1007/s40273-015-0347-y. View

15.

Elshout M, van der Reis M, Webers C, Schouten J . The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters. Graefes Arch Clin Exp Ophthalmol. 2014; 252(12):1911-20. DOI: 10.1007/s00417-014-2641-3. View

16.

DAmico D, Goldberg M, Hudson H, Jerdan J, Krueger D, Luna S . Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology. 2003; 110(12):2372-83. DOI: 10.1016/j.ophtha.2003.08.020. View

17.

. Occult choroidal neovascularization. Influence on visual outcome in patients with age-related macular degeneration. Macular Photocoagulation Study Group. Arch Ophthalmol. 1996; 114(4):400-12. View

18.

Bowker S, Pohar S, Johnson J . A cross-sectional study of health-related quality of life deficits in individuals with comorbid diabetes and cancer. Health Qual Life Outcomes. 2006; 4:17. PMC: 1435871. DOI: 10.1186/1477-7525-4-17. View

19.

Gragoudas E, Adamis A, Cunningham Jr E, Feinsod M, Guyer D . Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351(27):2805-16. DOI: 10.1056/NEJMoa042760. View

20.

Krebs I, Stolba U, Glittenberg C, Seyeddain O, Benesch T, Binder S . Prognosis of untreated occult choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2006; 245(3):376-84. DOI: 10.1007/s00417-006-0424-1. View